Abstract: OBJECTIVE To explore the pharmaceutical care strategy of the effects of clozapine exposure during pregnancy on maternal and infant and to provide references for the pharmaceutical care of pregnant patients with schizophrenia. METHODS Clinical pharmacist participated in the whole process of treatment of a schizophrenic patient who was exposed to clozapine during pregnancy before delivery, after delivery and neonatal treatment and treated the complications of pregnancy caused by clozapine exposure during pregnancy, drug treatment during delivery, and the impact of maternal adverse reactions on neonatal treatment and post-delivery medications would assist the clinic in individualized medication monitoring for special populations. RESULTS The clinical pharmacist assisted the physician in the estimated monitoring and treatment by assisting decision-making. The patient delivered smoothly with no disease recurrence occurred, and the infant was discharged after the condition improved, and no clozapine exposure adverse events occurred. CONCLUSION Clinical pharmacists participate in the diagnosis and treatment process of clozapine exposure during pregnancy, assess the risk of drug treatment benefits and ensure the safety of patients' medication and medical safety.